Audrey C. Bochi-Layec

Audrey C. Bochi-Layec

Auto-generated profile, based on publicly available information

Audrey C. Bochi-Layec

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2026 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MHMatthew Ho
Matthew Ho
LPLuca Paruzzo
Luca Paruzzo
JNJulia Han Noll
Julia Han Noll
FSFederico Stella
Federico Stella
PDPooja Devi
Pooja Devi
JFJoseph A. Fraietta
Joseph A. Fraietta

4 February 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
ICIvan J. Cohen
Ivan J. Cohen
ABAudrey C. Bochi-Layec
Audrey C. Bochi-Layec
JLJean Lemoine
Jean Lemoine
SJScott Jenks
Scott Jenks
PBPedram Bayat
Pedram Bayat
MRMarco Ruella
Marco Ruella
Current US Food and Drug Administration–approved chimeric antigen receptor (CAR) T cell therapies for B cell leukemias and lymphomas target CD19, which is widely expressed across the B cell lineage, often leading to on-target, off-tumor B cell depletion, prolonged immune suppression, and antigen-negative escape in a subset of patients. In contrast, B cell receptor (BcR) signaling is essential for the survival of most mature B cell neoplasms, and BcRs carrying the immunoglobulin heavy variable gene IGHV4-34 are highly enriched in B cell malignancies compared with normal B cells. Further, self-reactive IGHV4-34 + serum autoantibodies are enriched in aggressive systemic lupus erythematosus (SLE) and other autoimmune diseases. Here, we developed CAR T cells targeting the BcR carrying IGHV4-34 (CART4-34). We found that CART4-34 showed specific cytotoxicity and cytokine secretion toward IGHV4-34 + malignant B cells. In addition, although CD19 was down-regulated upon relapse after treatment with CART19, IGHV4-34 + BcR levels remained intact upon relapse after treatment with CART4-34, suggesting reduced risk of antigen-negative escape. In IGHV4-34 + HBL1 cell line–derived xenograft mouse models, CART4-34 showed robust expansion and antitumor activity comparable to those of CART19. Optimized CAR:BcR binding using shorter CAR hinge domains improved immune synapse morphology and in vivo activity. In addition, we showed that CART4-34 could target human IGHV4-34 + SLE B cells and deplete IGHV4-34 + autoantibodies ex vivo, without targeting healthy B cells or affecting total IgG titers. In conclusion, we developed a CAR T cell product that specifically targets pathogenic B cells in lymphoid malignancies and SLE, offering potential for precision cell therapy for these indications.

3 August 2026 in Molecular Therapy Oncology
Verified
Journal Article
Open access
ABAudrey C. Bochi-Layec
Audrey C. Bochi-Layec
ICIvan J. Cohen
Ivan J. Cohen
JLJean Lemoine
Jean Lemoine
MRMarco Ruella
Marco Ruella